account_balance
Investment manager · 13F filer · SEC CIK 2013410
Fcpm Iii Services B.v.
Reported value$750Mas of Jun 30, 2026
Positions11 1 new, 0 sold out
Top 10 weight100%NAMS alone is 38%
FiledAug 1445 days after quarter end
Portfolio · as of Jun 30, 2026
Where the money is
New or addedTrimmedHeld
NAMS
Newamsterdam Pharma Company
38.3%Trimmed
MPLT
Maplight Therapeutics INC
15.4%
DYN
Dyne Therapeutics INC
11.4%Trimmed
VOR
Vor Biopharma INC
10.1%
DMRA
Damora Therapeutics INC
8.5%
REPL
Replimune Group INC
4.1%
CBIO
Crescent Biopharma Inc.
4.0%
AURA
Aura Biosciences INC
3.8%New
Engene Holdings INC
Engene Holdings INC
2.2%
BCYC
Bicycle Therapeutics PLC
2.0%
1 others
0.1%
Box size is the share of the fund's reported holdings. 13F only covers US-listed stocks, so foreign holdings and short positions are missing.
What changed